These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 29989572)

  • 21. Development of tetravalent IgG1 dual targeting IGF-1R-EGFR antibodies with potent tumor inhibition.
    Croasdale R; Wartha K; Schanzer JM; Kuenkele KP; Ries C; Mayer K; Gassner C; Wagner M; Dimoudis N; Herter S; Jaeger C; Ferrara C; Hoffmann E; Kling L; Lau W; Staack RF; Heinrich J; Scheuer W; Stracke J; Gerdes C; Brinkmann U; Umana P; Klein C
    Arch Biochem Biophys; 2012 Oct; 526(2):206-18. PubMed ID: 22464987
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bispecific antibodies for polyclonal T-cell engagement.
    Baeuerle PA; Kufer P; Lutterbüse R
    Curr Opin Mol Ther; 2003 Aug; 5(4):413-9. PubMed ID: 14513685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Generation of dual-variable-domain immunoglobulin molecules for dual-specific targeting.
    Gu J; Ghayur T
    Methods Enzymol; 2012; 502():25-41. PubMed ID: 22208980
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy: Technological Considerations.
    Shim H
    Biomolecules; 2020 Feb; 10(3):. PubMed ID: 32111076
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting T cells with bispecific antibodies for cancer therapy.
    Lum LG; Thakur A
    BioDrugs; 2011 Dec; 25(6):365-79. PubMed ID: 22050339
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bispecific antibodies: molecules that enable novel therapeutic strategies.
    Fischer N; Léger O
    Pathobiology; 2007; 74(1):3-14. PubMed ID: 17496428
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapeutic strategies in neuroblastoma: antitumoral activity of deglycosylated Ricin A conjugated anti-GD2 antibodies and anti-CD3xanti-GD2 bispecific antibodies.
    Manzke O; Russello O; Leenen C; Diehl V; Bohlen H; Berthold F
    Med Pediatr Oncol; 2001 Jan; 36(1):185-9. PubMed ID: 11464879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Bispecific antibodies, novel therapeutic candidates harnessing the immune system].
    Chames P; Wurch T
    Med Sci (Paris); 2019 Dec; 35(12):1072-1082. PubMed ID: 31903920
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The manufacturing considerations of bispecific antibodies.
    Underwood DJ; Bettencourt J; Jawad Z
    Expert Opin Biol Ther; 2022 Aug; 22(8):1043-1065. PubMed ID: 35771976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diabodies: molecular engineering and therapeutic applications.
    Wu C
    Drug News Perspect; 2009 Oct; 22(8):453-8. PubMed ID: 20016854
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Engineering of stable bispecific antibodies targeting IL-17A and IL-23.
    Mabry R; Lewis KE; Moore M; McKernan PA; Bukowski TR; Bontadelli K; Brender T; Okada S; Lum K; West J; Kuijper JL; Ardourel D; Franke S; Lockwood L; Vu T; Frank A; Appleby MW; Wolf A; Reardon B; Hamacher NB; Stevens B; Lewis P; Lewis KB; Gilbertson DG; Lantry M; Julien SH; Ostrander C; Chan C; Byrnes-Blake K; Brody J; Presnell S; Meengs B; Levin SD; Snavely M
    Protein Eng Des Sel; 2010 Mar; 23(3):115-27. PubMed ID: 20022918
    [TBL] [Abstract][Full Text] [Related]  

  • 32. 2nd PEGS Annual Symposium on Antibodies for Cancer Therapy: April 30-May 1, 2012, Boston, USA.
    Ho M; Royston I; Beck A
    MAbs; 2012; 4(5):562-70. PubMed ID: 22864478
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Generation and characterization of bispecific tandem diabodies for tumor therapy.
    Kipriyanov SM
    Methods Mol Biol; 2003; 207():323-33. PubMed ID: 12412483
    [No Abstract]   [Full Text] [Related]  

  • 34. CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis.
    Mølhøj M; Crommer S; Brischwein K; Rau D; Sriskandarajah M; Hoffmann P; Kufer P; Hofmeister R; Baeuerle PA
    Mol Immunol; 2007 Mar; 44(8):1935-43. PubMed ID: 17083975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bioassay Development for Bispecific Antibodies-Challenges and Opportunities.
    Register AC; Tarighat SS; Lee HY
    Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069573
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular engineering strategies and methods for the expression and purification of IgG1-based bispecific bivalent antibodies.
    Dimasi N; Fleming R; Wu H; Gao C
    Methods; 2019 Feb; 154():77-86. PubMed ID: 30102989
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Bispecific antibodies: what future?].
    Pèlegrin A; Robert B
    Med Sci (Paris); 2009 Dec; 25(12):1155-8. PubMed ID: 20035697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Therapeutic antibodies against cancer.
    Adler MJ; Dimitrov DS
    Hematol Oncol Clin North Am; 2012 Jun; 26(3):447-81, vii. PubMed ID: 22520975
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy.
    Acheampong DO; Adokoh CK; Ampomah P; Agyirifor DS; Dadzie I; Ackah FA; Asiamah EA
    Protein Pept Lett; 2017; 24(5):456-465. PubMed ID: 28117014
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current perspectives of bispecific antibody-based immunotherapy.
    Talac R; Nelson H
    J Biol Regul Homeost Agents; 2000; 14(3):175-81. PubMed ID: 11037049
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.